University at Buffalo
Study: Memory deficits resulting from epigenetic changes in Alzheimer’s disease can be reversed
In preclinical study, researchers have identified new genes that could be key therapeutic targets for treating Alzheimer’s disease
Zhen Yan, PhD, SUNY Distinguished Professor, Department of Physiology and Biophysics
Jacobs School of Medicine and Biomedical Sciences
BUFFALO, N.Y. – Memory loss associated with Alzheimer’s disease (AD) may be able to be restored by inhibiting certain enzymes involved in abnormal gene transcription, according to a preclinical study by researchers at the University at Buffalo. The findings could pave the way toward new treatments for Alzheimer’s disease.
Zhen Yan, SUNY Distinguished Professor
Department of Physiology and Biophysics
Memory loss associated with Alzheimer’s disease (AD) may be able to be restored by inhibiting certain enzymes involved in abnormal gene transcription, according to a preclinical study by UB researchers. The findings could pave the way toward new treatments for Alzheimer’s disease.
The paper was published Dec. 9 in Science Advances.
“By treating AD mouse models with a compound to inhibit these enzymes, we were able to normalize gene expression, restore neuronal function and ameliorate cognitive impairment,” says senior author Zhen Yan, SUNY Distinguished Professor in the Department of Physiology and Biophysics in the Jacobs School of Medicine and Biomedical Sciences at UB.